{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:57:01Z","timestamp":1793350621886,"version":"4.5.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"\n Importance<\/jats:title>\n Glucagon-like peptide 1 receptor agonists (GLP1R) are increasingly being used for the treatment of obesity in adolescents. It is currently unknown whether GLP1R treatment is associated with suicidal ideation or attempts in this population.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association between GLP1R initiation and suicidal ideation or attempts in adolescents with obesity.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective propensity score\u2013matched cohort study using electronic health records from the TriNetX global federated network between December 2019 and June 2024. The analysis included data from 120 health care organizations, mainly from the USA. Participants were adolescents aged 12 to 18 years with a diagnosis of obesity and evidence of an antiobesity GLP1R prescription or lifestyle intervention without GLP1R within the following year. Cohorts were balanced for baseline demographic characteristics, psychiatric medications and comorbidities, and diagnoses associated with socioeconomic status and health care access using propensity score matching.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Initial prescription of GLP1R (study cohort) or lifestyle intervention without GLP1R (control cohort).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Incidence of suicidal ideation or attempts based on\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n codes recorded in patient electronic health records during 12 months of follow-up. Diagnoses of upper respiratory tract infections (URTI) were used as negative control outcomes, and gastrointestinal symptoms (GI) were used as positive control outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 4052 adolescents with obesity and a concomitant antiobesity intervention were identified for the GLP1R cohort and 50\u202f112 were identified for the control cohort. Propensity score matching resulted in 3456 participants in each balanced cohort. Prescription of GLP1R was associated with a 33% reduced risk for suicidal ideation or attempts over 12 months of follow-up (1.45% vs 2.26%; hazard ratio [HR], 0.67; 95% CI, 0.47-0.95;\n P\u2009=\u2009<\/jats:italic>\n .02) and a higher rate of GI symptoms (6.9% vs 5.4%; HR, 1.41; 95% CI, 1.12-1.78;\n P<\/jats:italic>\n \u2009=\u2009.003) but no difference in rates of URTI diagnoses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, adolescents with obesity prescribed a GLP1R had a lower incidence of suicidal ideation or attempts compared with matched patients not prescribed GLP1R who were treated with lifestyle intervention. These results suggest a favorable psychiatric safety profile of GLP1R in adolescents. The detected reduction in HRs for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2024.3812","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:01:03Z","timestamp":1728903663000},"page":"1307","source":"Crossref","is-referenced-by-count":43,"title":["Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists"],"prefix":"10.1001","volume":"178","author":[{"given":"Liya","family":"Kerem","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hadassah University Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Stokar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"Department of Internal Medicine, Department of Endocrinology, Hadassah University Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"poi240067r1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity.","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"10113","key":"poi240067r2","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults.","volume":"390","author":"Collaboration","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"poi240067r3","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa1703860","article-title":"Simulation of growth trajectories of childhood obesity into adulthood.","volume":"377","author":"Ward","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"poi240067r4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00168-7","article-title":"Childhood obesity beyond COVID-19.","volume":"6","author":"The Lancet Public Health","year":"2021","journal-title":"Lancet Public Health"},{"issue":"1","key":"poi240067r5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-023-00435-4","article-title":"Child and adolescent obesity.","volume":"9","author":"Lister","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"poi240067r6","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/dc19-1988","article-title":"Adolescent obesity and early-onset type 2 diabetes.","volume":"43","author":"Twig","year":"2020","journal-title":"Diabetes Care"},{"issue":"25","key":"poi240067r7","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","article-title":"Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood.","volume":"374","author":"Twig","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"poi240067r8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"poi240067r9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cell.2019.03.028","article-title":"Polygenic prediction of weight and obesity trajectories from birth to adulthood.","volume":"177","author":"Khera","year":"2019","journal-title":"Cell"},{"issue":"3","key":"poi240067r10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s42255-022-00549-1","article-title":"Characterization of the genetic architecture of infant and early childhood body mass index.","volume":"4","author":"Helgeland","year":"2022","journal-title":"Nat Metab"},{"issue":"12","key":"poi240067r11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/2013.jamapediatrics.319","article-title":"Response of severely obese children and adolescents to behavioral treatment.","volume":"166","author":"Danielsson","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"11","key":"poi240067r12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41366-018-0230-y","article-title":"Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews.","volume":"42","author":"Ells","year":"2018","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"poi240067r13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41574-023-00858-9","article-title":"Current and future pharmacotherapies for obesity in children and adolescents.","volume":"19","author":"Kelly","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"poi240067r14","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13686","article-title":"The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: a systematic review and meta-analysis.","volume":"25","author":"Wang","year":"2024","journal-title":"Obes Rev"},{"key":"poi240067r15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/issn.1421-7082","article-title":"Glucagon-like peptide-1 receptor agonist treatment for pediatric obesity.","volume":"30","author":"Kelly","year":"2016","journal-title":"Endocr Dev"},{"key":"poi240067r16","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis.","author":"Chen","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"poi240067r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review.","volume":"164","author":"Cooper","year":"2023","journal-title":"J Psychiatr Res"},{"key":"poi240067r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105298","article-title":"Clinical insights into the cross-link between mood disorders and type 2 diabetes: a review of longitudinal studies and Mendelian randomisation analyses.","volume":"152","author":"Possidente","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"poi240067r19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/ijms23020739","article-title":"GLP-1a: going beyond traditional use.","volume":"23","author":"Laurindo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"poi240067r20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","article-title":"Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function.","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol"},{"key":"poi240067r21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1238353","article-title":"Case report: semaglutide-associated depression: a report of two cases.","volume":"14","author":"Li","year":"2023","journal-title":"Front Psychiatry"},{"issue":"11","key":"poi240067r22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials.","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"poi240067r24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"poi240067r25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"issue":"8","key":"poi240067r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6708a1","article-title":"Youth risk behavior surveillance - United States, 2017.","volume":"67","author":"Kann","year":"2018","journal-title":"MMWR Surveill Summ"},{"issue":"7","key":"poi240067r28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/obr.12535","article-title":"Exploring the association between childhood and adolescent obesity and depression: a meta-analysis.","volume":"18","author":"Quek","year":"2017","journal-title":"Obes Rev"},{"key":"poi240067r29","article-title":"Trends in the relationship between suicide behaviors and obesity among adolescents in the United States from 1999 to 2019.","author":"Iwatate","year":"2023","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"23","key":"poi240067r30","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023.","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"poi240067r32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.13063\/2327-9214.1244","article-title":"A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data.","volume":"4","author":"Kahn","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"poi240067r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2021.103847","article-title":"Assessing real-world medication data completeness.","volume":"119","author":"Evans","year":"2021","journal-title":"J Biomed Inform"},{"issue":"2","key":"poi240067r34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA.","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"poi240067r35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"poi240067r36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period.","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"poi240067r37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamapediatrics.2022.0945","article-title":"Incidence rates and clinical outcomes of SARS-CoV-2 infection with the omicron and delta variants in children younger than 5 years in the US.","volume":"176","author":"Wang","year":"2022","journal-title":"JAMA Pediatr"},{"key":"poi240067r38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173","article-title":"cardiovascular safety of romosozumab vs pth analogs for osteoporosis treatment: a propensity score matched cohort study.","author":"Stokar","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"poi240067r39","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"poi240067r40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"poi240067r41","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing e-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"4","key":"poi240067r42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"poi240067r43","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"issue":"22","key":"poi240067r44","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity.","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"poi240067r45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity.","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"poi240067r46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/17477160903473697","article-title":"Self-esteem and quality of life in obese children and adolescents: a systematic review.","volume":"5","author":"Griffiths","year":"2010","journal-title":"Int J Pediatr Obes"},{"issue":"1","key":"poi240067r47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11920-019-0990-7","article-title":"Obesity in adolescents with psychiatric disorders.","volume":"21","author":"Chao","year":"2019","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"poi240067r48","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/oby.20084","article-title":"Adolescent suicidal behavior across the excess weight status spectrum.","volume":"21","author":"Zeller","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"poi240067r49","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/add.15446","article-title":"Food addiction in a large community sample of Canadian adults: prevalence and relationship with obesity, body composition, quality of life and impulsivity.","volume":"116","author":"Minhas","year":"2021","journal-title":"Addiction"},{"key":"poi240067r50","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.psychres.2018.08.100","article-title":"Suicidal ideation and attempts in patients who seek treatment for substance use disorder.","volume":"269","author":"L\u00f3pez-Go\u00f1i","year":"2018","journal-title":"Psychiatry Res"},{"issue":"4","key":"poi240067r51","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"12","key":"poi240067r52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"6","key":"poi240067r53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13513","article-title":"Temporal trends in suicidal ideation and attempts among US adolescents by sex and race\/ethnicity, 1991-2019.","volume":"4","author":"Xiao","year":"2021","journal-title":"JAMA Netw Open"},{"key":"poi240067r23","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. July 11, 2023. Accessed August 5, 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists"},{"key":"poi240067r26","doi-asserted-by":"crossref","unstructured":"Curtin? SC, Tejada-Vera? B, Bastian? BA. Deaths: Leading Causes for 2020. December 5, 2023. Accessed August 5, 2024. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr72\/nvsr72-13.pdf","DOI":"10.15620\/cdc:133059"},{"key":"poi240067r31","unstructured":"TriNetX. Clinical data platform. Accessed August 5, 2024. https:\/\/trinetx.com"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2824895\/jamapediatrics_kerem_2024_oi_240067_1732566607.0234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:02:39Z","timestamp":1733137359000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2824895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2024.3812","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}